Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)

Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)

Background Antitumor vaccines targeting tumor-associated antigens (TAAs) can generate antitumor immune response. A novel vaccine platform using adenovirus 5 (Ad5) vectors [E1–, E2b–] targeting three TAAs—prostate-specific antigen (PSA), brachyury, and MUC-1—has been developed. Both brachyury and the...

Full description

Bibliographic Details
Main Authors: Renee N Donahue, Jeffrey Schlom, James L Gulley, Ravi A Madan, Claudia Palena, Caroline Jochems, Shahrooz Rabizadeh, Patrick Soon-Shiong, Sheri McMahon, Julius Strauss, Marijo Bilusic, Fatima Karzai, Houssein Abdul Sater, Jennifer L Marté, Yo-Ting Tsai, Jason Redman, Charalampos Floudas
Format: Article
Language:English
Published: BMJ Publishing Group 2021-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/3/e002374.full

Internet

https://jitc.bmj.com/content/9/3/e002374.full

Similar Items